Zhenchang Sun1,2, Wenjuan Wan3, Xudong Zhang1,2, Lei Zhang1,2, Xin Li1,2, Ling Li1,2, Xinhua Wang1,2, Feifei Nan1,2, Hui Yu1,2, Yu Chang1,2, Jiaqin Yan1,2, Zhaoming Li1,2, Fangfang Cui4, Jurui Ge1,2, Yaqin Duo XiaXu1,2, Xia Xu1,2, Xiaorui Fu5,6, Mingzhi Zhang7,8. 1. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. 2. Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China. 3. Department of Oncology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. 4. National Engineering Laboratory for Internet Medical Systems and Applications, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. 5. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. zymfxr_2006@126.com. 6. Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China. zymfxr_2006@126.com. 7. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. mingzhi_zhang1@163.com. 8. Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China. mingzhi_zhang1@163.com.
Abstract
PURPOSE: To investigate the clinical characteristics and prognostic factors of natural killer/T-cell lymphoma (NKTCL). METHODS: We retrospectively reviewed 410 NKTCL patients admitted to our lymphoma center from 2000 to 2019. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan-Meier method, and the differences between the study groups were compared by the log-rank test. RESULTS: The median age of the 410 patients was 44 (range 8-84), and the 5-year OS and PFS were 61.2% and 38.4%, respectively. For patients with stage I/II, the 5-year PFS rate was 57.5%, and the 5-year OS rate was 77.2%. For patients with stage III/IV, the 5-year PFS rate was 17.4%, and the 5-year OS rate was 43.7%. Compared to the patients who received radiotherapy alone or chemotherapy alone as their initial treatment, the patients who received combined chemoradiotherapy had longer PFS (P = 0.013). Independent prognostic factors for OS were stage III/IV (P = 0.001), elevated IPI/aaIPI score (P = 0.019), elevated PINK score (P < 0.001) and elevated plasma EBV-DNA (P = 0.003). An elevated PINK score (P < 0.001) was an independent prognostic factor for PFS. CONCLUSION: Stage III/IV, elevated IPI/aaIPI score, elevated PINK score and elevated plasma EBV-DNA were independent prognostic factors for OS. Elevated PINK score was an independent prognostic factor for PFS. In stage III/IV patients, the patients who received combined chemoradiotherapy had significantly longer PFS.
PURPOSE: To investigate the clinical characteristics and prognostic factors of natural killer/T-cell lymphoma (NKTCL). METHODS: We retrospectively reviewed 410 NKTCL patients admitted to our lymphoma center from 2000 to 2019. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan-Meier method, and the differences between the study groups were compared by the log-rank test. RESULTS: The median age of the 410 patients was 44 (range 8-84), and the 5-year OS and PFS were 61.2% and 38.4%, respectively. For patients with stage I/II, the 5-year PFS rate was 57.5%, and the 5-year OS rate was 77.2%. For patients with stage III/IV, the 5-year PFS rate was 17.4%, and the 5-year OS rate was 43.7%. Compared to the patients who received radiotherapy alone or chemotherapy alone as their initial treatment, the patients who received combined chemoradiotherapy had longer PFS (P = 0.013). Independent prognostic factors for OS were stage III/IV (P = 0.001), elevated IPI/aaIPI score (P = 0.019), elevated PINK score (P < 0.001) and elevated plasma EBV-DNA (P = 0.003). An elevated PINK score (P < 0.001) was an independent prognostic factor for PFS. CONCLUSION: Stage III/IV, elevated IPI/aaIPI score, elevated PINK score and elevated plasma EBV-DNA were independent prognostic factors for OS. Elevated PINK score was an independent prognostic factor for PFS. In stage III/IV patients, the patients who received combined chemoradiotherapy had significantly longer PFS.
Authors: Michel de Weers; Yu-Tzu Tai; Michael S van der Veer; Joost M Bakker; Tom Vink; Daniëlle C H Jacobs; Lukas A Oomen; Matthias Peipp; Thomas Valerius; Jerry W Slootstra; Tuna Mutis; Wim K Bleeker; Kenneth C Anderson; Henk M Lokhorst; Jan G J van de Winkel; Paul W H I Parren Journal: J Immunol Date: 2010-12-27 Impact factor: 5.422
Authors: Maher K Gandhi; Eleanore Lambley; Jacqueline Burrows; Ujjwal Dua; Suzanne Elliott; Peter J Shaw; H Miles Prince; Max Wolf; Kerrie Clarke; Craig Underhill; Tony Mills; Peter Mollee; Devinder Gill; Paula Marlton; John F Seymour; Rajiv Khanna Journal: Clin Cancer Res Date: 2006-01-15 Impact factor: 12.531
Authors: Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: A Gallagher; A A Armstrong; J MacKenzie; L Shield; G Khan; A Lake; S Proctor; P Taylor; G B Clements; R F Jarrett Journal: Int J Cancer Date: 1999-08-20 Impact factor: 7.396
Authors: K C Allen Chan; Jun Zhang; Anthony T C Chan; Kenny I K Lei; Sing-Fai Leung; Lisa Y S Chan; Katherine C K Chow; Y M Dennis Lo Journal: Cancer Res Date: 2003-05-01 Impact factor: 12.701